Albireo clinical trials

Acquired by Ipsen, Mar 2, 2023 · source ↗

The registry lists 16 studies whose lead sponsor is Albireo. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 16 of 16. All Ipsen studies →

• Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeActive, not recruitingNCT05035030Phase 3

  Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen

• An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat in Children With Biliary AtresiaActive, not recruitingNCT05426733Phase 3

  Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen

• Long Term Safety & Efficacy Study Evaluating The Effect of A4250 in Children With PFICCompletedNCT03659916Phase 3

  Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen

• Odevixibat for the Treatment of Progressive Familial Intrahepatic CholestasisNo longer availableNCT04483531

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Undergone a Kasai HPE (BOLD)CompletedNCT04336722Phase 3

  Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen

• Safety and Tolerability of A3907 in Primary Sclerosing CholangitisTerminatedNCT05642468Phase 2

  Sponsor listed in the registry: Albireo, an Ipsen Company · First submitted before Albireo became part of Ipsen

• A Phase 2 Study of Elobixibat in Adults With NAFLD or NASHCompletedNCT04006145Phase 2

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2CompletedNCT03566238Phase 3

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• A4250, an IBAT Inhibitor in Pediatric CholestasisCompletedNCT02630875Phase 2

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy SubjectsCompletedNCT03082937Phase 1

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• Study of A4250 in Healthy Volunteers Under Fasting, Fed and Sprinkled ConditionsCompletedNCT03608319Phase 1

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• Double-blind, Randomised Study of A3384 in BAM/BADCompletedNCT02078856Phase 2

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• Study of A3309 in Patients With DyslipidemiaCompletedNCT01069783Phase 2

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384CompletedNCT02963077Phase 1

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• Efficacy and Safety of Odevixibat in Patients With Alagille SyndromeCompletedNCT04674761Phase 3

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen

• Study of Elobixibat (A3309) in Patients With Chronic Idiopathic ConstipationCompletedNCT01007123Phase 2

  Sponsor listed in the registry: Albireo · First submitted before Albireo became part of Ipsen